New hope for Hard-to-Treat breast cancer: drug trial targets advanced TNBC

NCT ID NCT06189209

Recruiting now Disease control Sponsor: Rhizen Pharmaceuticals SA Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called tenalisib in 40 people with metastatic triple negative breast cancer (TNBC) who have already tried 1 to 3 other treatments. The goal is to see if tenalisib can shrink tumors or stop them from growing for at least 16 weeks. Researchers will also monitor side effects and drug levels in the blood.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER (TNBC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE-NEGATIVE BREAST CANCER (TNBC)

Contacts and locations

Locations

HCG City Cancer Center
RECRUITING

Vijayawada, Andhra Pradesh, 520002, India
Health Point Hospital
RECRUITING

Kolkata, West Bengal, 700025, India
Meenakshi Mission Hospital & Research Center
NOT_YET_RECRUITING

Madurai, Tamil Nadu, 625107, India
Mumbai Oncocare Centre
RECRUITING

Mumbai, Maharashtra, 400056, India
Narayana Hrudayala Majumdar Shaw Hospital
RECRUITING

Bangalore, Karnataka, 560099, India
Nizams Institute of Medical Science
NOT_YET_RECRUITING

Hyderabad, Telangana, 500082, India
Nobel Hospital
RECRUITING

Pune, Maharashtra, 411013, India
Sahyadri Super Speciality Hospital
RECRUITING

Pune, Maharashtra, 411004, India
Tata Memorial Centre
RECRUITING

Mumbai, Maharashtra, 400012, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.